Cristian Villanueva - Concepedia

Author

Cristian Villanueva

Centre Hospitalier Universitaire de Besançon

Also Known As

C Villanueva, C. Villanueva, C.B. Villanueva, Carola Ariza Villanueva, Cristian B. Villanueva, Cristian Villanueva, Dominique Spaeth, Mony Ung

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier Universitaire de Besançon Inserm Sarah Cannon Institut de Cancérologie de l'Ouest

About

Cristian Villanueva is an author at Centre Hospitalier Universitaire de Besançon specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	992
2	Health Sciences	2	2	39
3	Immunology	2	2	39
4	Cell Biology	1	1	14
5	Emergency Medicine	1	1	62

Cristian Villanueva

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, New England Journal of Medicine	2016	1.9K
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial Jan B. Vermorken, Jan Stöhlmacher-Williams, Lisa Licitra, The Lancet Oncology Metastatic Squamous-cell CarcinomaOpen-label Phase 3MedicinePathologyHead And Neck Cancer	2013	432
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial Gϋnter von Minckwitz, Fabio Puglisi, Javier Cortés, The Lancet Oncology Metastatic Breast CancerChemotherapy Versus ChemotherapyBreast OncologyMedicineRandomised Phase 3	2014	145
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial Xavier Pivot, Gilles Romieu, Marc Debled, The Lancet Breast OncologyOncologyEarly Breast CancerRandomised TrialBreast Cancer	2019	125
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial Joyce O’Shaughnessy, Katarína Petráková, Gabe S. Sonke, Breast Cancer Research and Treatment	2017	108
Discordances in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and Metastasis Elsa Curtit, Virginie Nerich, Laura Mansi, The Oncologist	2013	92
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial Gabe S. Sonke, Lowell L. Hart, Mario Campone, Breast Cancer Research and Treatment	2017	91
Discordance in early breast cancer for tumour grade, Estrogen Receptor, Progesteron Receptors and Human Epidermal Receptor-2 status between core needle biopsy and surgical excisional primary tumour Véronique Lorgis, M.-P. Algros, Cristian Villanueva, The Breast	2011	74
Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Melanie Royce, Thomas Bachelot, Cristian Villanueva, JAMA Oncology	2018	65
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study Cristian Villanueva, Ahmad Awada, Mario Campone, European Journal of Cancer Taxane TreatmentOncologyPhase I/ii StudyMedicineBreast Cancer	2011	63

Page 1